Legal & General Group Plc Has $8.96 Million Holdings in LivaNova PLC $LIVN

Legal & General Group Plc boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 69.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 145,689 shares of the company’s stock after acquiring an additional 59,477 shares during the period. Legal & General Group Plc’s holdings in LivaNova were worth $8,964,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. grew its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming purchased a new position in LivaNova during the second quarter valued at approximately $31,000. Quarry LP purchased a new position in LivaNova during the third quarter valued at approximately $36,000. EverSource Wealth Advisors LLC grew its position in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares in the last quarter. Finally, Covestor Ltd grew its position in LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on LIVN shares. Robert W. Baird decreased their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Piper Sandler reissued an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a research report on Wednesday, February 25th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Finally, Needham & Company LLC boosted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Price Performance

NASDAQ LIVN opened at $73.72 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The company has a fifty day simple moving average of $67.40 and a 200 day simple moving average of $64.88. The company has a market cap of $4.05 billion, a P/E ratio of 37.81 and a beta of 0.88. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $75.82.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same period in the prior year, the firm earned $0.88 EPS. The business’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts predict that LivaNova PLC will post 3.72 EPS for the current year.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.